Leone, Jose Pablo
Emblem, Kyrre E.
Weitz, Michelle
Gelman, Rebecca S.
Schneider, Bryan P.
Freedman, Rachel A.
Younger, Jerry
Pinho, Marco C.
Sorensen, A. Gregory
Gerstner, Elizabeth R.
Harris, Gordon
Krop, Ian E.
Morganstern, Daniel
Sohl, Jessica
Hu, Jiani
Kasparian, Elizabeth
Winer, Eric P.
Lin, Nancy U. http://orcid.org/0000-0003-2263-5413
Funding for this research was provided by:
American Society of Clinical Oncology Career Development Award (n/a)
Breast Cancer Research Foundation (n/a)
Dana-Farber Cancer Institute Women’s Cancers Program Executive Council Personalized Medicine Award (n/a)
South-Eastern Norway Regional Health Authority (2016102 and 2013069)
Norwegian Cancer Society (6817564)
Genentech (n/a)
Article History
Received: 29 July 2020
Accepted: 15 November 2020
First Online: 30 November 2020
Ethics approval and consent to participate
: The protocol was approved by the Dana-Farber/Harvard Cancer Center (DF/HCC) Scientific Review Committee and Institutional Review Board. All study participants provided written informed consent prior to any study-related procedures.
: Not applicable.
: Harris: Member, Novometrics LLC, IQ Medical Imaging LLC; Scientific Advisory Board, Fovia Inc.Krop: Institutional research funding from Genentech/Roche, Pfizer, and Daiichi-Sankyo; advisory board participant/consultant for Genentech/Roche, Daiichi-Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Bristol-Myers Squibb, Celltrion Pharma, Merck (DSMC), Novartis (DSMB); honoraria from Genentech/Roche, Daiichi-Sankyo, Macrogenics, Context Therapeutics, Taiho.Morganstern: advisory role and honoraria for PUMA pharmaceuticals.Winer: Institutional research funding from Genentech/Roche; consultant/honoraria from Genentech/Roche, GSK and Seattle Genetics (each < $5000).Lin: Consulting for Puma, Seattle Genetics, Daichii Sankyo though none would have a financial interest in the results or materials of this study.